Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines

Laboratory Investigation

Volumn 77, Issue 6, 1997, Pages 677-684

  Yasunaga, Yutaka ^a   Nakanishi, Hirofumi ^a   Naka, Norifumi ^a   Miki, Tsuneharu ^a   Tsujimura, Takahiro ^b   Itatani, Hiroaki ^b   Okuyama, Akihiko ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINE; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; DYSPLASIA; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AMINES; CARCINOMA, TRANSITIONAL CELL; HUMANS; MALE; MIDDLE AGED; MUTATION; OCCUPATIONAL DISEASES; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0031474795     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Boyland E, Kinder CH, and Manson D (1960). Effect of 1:4-saccharinolactone on induction of bladder cancer. Ann Rep Br Emp Cancer Campaign 38:45-49.
2. Bressac B, Kew M, Wands J, and Ozturk M (1991). Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431.
3. Case RAM, Hosker ME, McDonald DB, and Pearson JT (1954). Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry: Part I - The role of aniline, benzidine, and β-naphtylamine. Br J Indust Med 11:75-104.
4. Chen BF and Clejan S (1993). Rapid preparation of tissue DNA fom paraffin-embedded blocks and analysis by polymerase chain reaction. J Histochem Cytochem 41:765-768.
5. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhage DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, and Minna JD (1990). Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603-1610.
6. D'Aquila RT, Bechtel LJ, Videler JA, Eron JJ, Gorczyca P, and Kaplan JC (1991). Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucleic Acids Res 19: 3749.
7. Dolin PJ and Cook-Mozaffari P (1992). Occupation and bladder cancer: A death-certificate study. Br J Cancer 66: 568-578.
8. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, and Terada M (1992). Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52:1393-1398.
9. Fujita M, Inoue M, Tanizawa O, Iwamoto S, and Enomoto T (1992). Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 52:5323-5328.
10. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, and Yoshida O (1993a). Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342:1087-1088.
11. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, Hamazaki S, Toguchida J, Ishizaki K, Fujita J, Sugiyama T, and Yoshida O (1993b). Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 53:3795-3799.
12. Harris AL, Phil D, and Neal DE (1992). Bladder cancer-field versus clonal origin. N Engl J Med 326:759-761.
13. Hayes RB (1992). Biomarkers in occupational cancer epidemiology: Considerations in study design. Environ Health Perspect 98:149-154.
14. Hermanek P and Sobin LH, editors (1987). UICC (International Union Against Cancer): TNM classification of malignant tumors, 4th ed. Berlin: Springer Verlag.
15. Hollstein M, Marion M-J, Lehman T, Welsh J, Harris CC, Martel-Planche G, Kusters I, and Montesano R (1994). p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 15:1-3.
16. Hongyo T, Buzard GS, Calvert RJ, and Weghorst CM (1993). 'Cold SSCP': A simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res 21:3637-3642.
17. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF, and Rice JM (1995). Mutations of the K-ras and p53 genes in gastric adenocarcinoma from a high-incidence region around Florence, Italy. Cancer Res 55:2665-2672.
18. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, and Harris CC (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428.
19. Levine AJ, Momand J, and Finley CA (1991). The p53 tumour suppressor gene. Nature 351:453-456.
20. Lower GM (1982). Concepts in causality. Chemically induced human urinary bladder cancer. Cancer 49:1056-1066.
21. Meigs JW, Marrett LD, Ulrich FU, and Flannery JT (1986). Bladder tumor incidence among workers exposed to benzidine: A thirty-year follow up. J Natl Cancer Inst 76:1-8.
22. Mostofi FK, Sobin LH, and Torloni H (1973). Histological typing of urinary bladder tumours. Genova: WHO Press.
23. Petersen I, Ohgaki H, Ludeke BI, and Kleihues P (1993). p53 mutations in phenacetin-associated human urothelial carcinomas. Carcinogenesis 14:2119-2122.
24. Piolatto G, Negri E, Vecchia CL, Pira E, Decarli A, and Peto J (1991). Bladder cancer mortality of workers exposed to aromatic amines: An updated analysis. Br J Cancer 63:457-459.
25. Ramchurren N, Cooper K, and Summerhayes IC (1995). Molecular events underlying schistosomiasis-related bladder cancer. Int J Cancer 62:237-244.
26. Rehn L (1895). Blasengeschwulste bei Fuchsin-Arbeiten. Arch Klin Chir 50:588-600.
27. Schulte PA, Ringen K, Hemstreet GP, Altekruse EB, Gullen WH, Tillett S, Allsbrook WC, Crosby JH, Witherington R, and Stringer W (1986). Risk factors for bladder cancer in a cohort exposed to aromatic amines. Cancer 58:2156-2162.
28. Shibata A, Ohneseit PF, Tsai YC, Spruck CH III, Nichols PW, Chiang H-S, Lai M-K, and Jones PA (1994). Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15:1085-1087.
29. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, and Vogelstein B (1992). Clonal origin of bladder cancer. N Engl J Med 326:737-740.
30. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, and Vogelstein B (1991). Identification of p53 gene mutation in bladder cancers and urine samples. Science 252:706-709.
31. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, and Jones PA (1994). Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784-788.
32. Spruck CH III, Rideout WM III, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC, and Jones PA (1993). Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usage. Cancer Res 53:1162-1166.
33. Takahashi T, Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, and Ueda R (1991). The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775-1778.
34. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, and Anderson M (1994). p53 mutation hotspot in radon-associated lung cancer. Lancet 343:86-87.
35. Vecchia CL, Negri E, D'Avanzo B, and Franceschi S (1990). Occupation and the risk of bladder cancer. Int J Epidemiol 19:264-268.
36. Ward E, Carpenter A, Markowitz S, Roberts D, and Halperin W (1991). Excess number of bladder cancers in workers exposed to ortho-toluidine and aniline. J Natl Cancer Inst 83:501-506.
37. Warren W, Biggs PJ, El-Baz M, Ghoneim MA, Stratton MR, and Venitt S (1995). Mutations in the p53 gene in schistosomal bladder cancer: A study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis 16:1181-1189.